EuBiologics Co. Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen … Read more
EuBiologics Co. Ltd. (206650) - Total Assets
Latest total assets as of September 2025: ₩232.66 Billion KRW
Based on the latest financial reports, EuBiologics Co. Ltd. (206650) holds total assets worth ₩232.66 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EuBiologics Co. Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how EuBiologics Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
EuBiologics Co. Ltd. - Asset Composition Analysis
Current Asset Composition (September 2024)
EuBiologics Co. Ltd.'s total assets of ₩232.66 Billion consist of 41.1% current assets and 58.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.44 Billion | 3.2% |
| Accounts Receivable | ₩7.90 Billion | 3.9% |
| Inventory | ₩30.40 Billion | 15.0% |
| Property, Plant & Equipment | ₩76.10 Billion | 37.7% |
| Intangible Assets | ₩18.35 Billion | 9.1% |
| Goodwill | ₩888.92 Million | 0.4% |
Asset Composition Trend (2021–2024)
This chart illustrates how EuBiologics Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EuBiologics Co. Ltd.'s current assets represent 41.1% of total assets in 2024, an increase from 35.7% in 2021.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, down from 3.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 3.0% in 2021.
- Asset Diversification: The largest asset category is property, plant & equipment at 37.7% of total assets.
EuBiologics Co. Ltd. Competitors by Total Assets
Key competitors of EuBiologics Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
EuBiologics Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - EuBiologics Co. Ltd. generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, EuBiologics Co. Ltd. generates $9.46 in net profit.
EuBiologics Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.60 | 2.01 | 1.75 |
| Quick Ratio | 2.70 | 1.34 | 0.87 |
| Cash Ratio | 0.00 | 0.40 | 0.38 |
| Working Capital | ₩85.70 Billion | ₩ 30.24 Billion | ₩ 17.73 Billion |
EuBiologics Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between EuBiologics Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 33.1% |
| Total Assets | ₩202.08 Billion |
| Market Capitalization | $291.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values EuBiologics Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: EuBiologics Co. Ltd.'s assets grew by 33.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for EuBiologics Co. Ltd. (2021–2024)
The table below shows the annual total assets of EuBiologics Co. Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | ₩202.08 Billion | +33.12% |
| 2023-09-30 | ₩151.81 Billion | -6.33% |
| 2022-09-30 | ₩162.07 Billion | +7.73% |
| 2021-09-30 | ₩150.44 Billion | -- |